Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: Implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies

Journal of Molecular Histology

Volumn 41, Issue 1, 2010, Pages 39-50

  Franz, Marcus ^a   Brehm, Bernhard R ^a   Richter, Petra ^a   Gruen, Katja ^a   Neri, Dario ^b   Kosmehl, Hartwig ^c   Hekmat, Khosro ^a   Renner, Andre ^d   Gummert, Jan ^d   Figulla, Hans R ^a   Berndt, Alexander ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b ETH ZURICH   (Switzerland)

^c HELIOS KLINIKUM ERFURT   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Coronary artery disease; Fibronectin; Targeted therapy; Tenascin C; Valvular heart disease

Indexed keywords

FIBRONECTIN; HUMAN RECOMBINANT SMALL IMMUNOPROTEIN ANTIBODY; IMMUNOGLOBULIN ANTIBODY; MESSENGER RNA; TENASCIN; UNCLASSIFIED DRUG; ANTIBODY; CELL ADHESION MOLECULE; IMMUNOGLOBULIN; ISOPROTEIN;

ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG TARGETING; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; HEART RIGHT ATRIUM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN TARGETING; VALVULAR HEART DISEASE; ALTERNATIVE RNA SPLICING; CARDIOVASCULAR DISEASES; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HEART ATRIUM; HEART MUSCLE; HEART MUSCLE ISCHEMIA; METABOLISM; PATHOLOGY;

ALTERNATIVE SPLICING; ANTIBODIES; CARDIOVASCULAR DISEASES; CELL ADHESION MOLECULES; EXTRACELLULAR MATRIX; FIBRONECTINS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; HEART ATRIA; HEART VALVE DISEASES; HUMANS; IMMUNOPROTEINS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PROTEIN ISOFORMS; RNA, MESSENGER; TENASCIN;

EID: 77951090750     PISSN: 15672379     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10735-010-9260-z     Document Type: Article

References (59)

1. N Aso A Tamura M Nasu 2004 Circulating tenascin-C levels in patients with idiopathic dilated cardiomyopathy Am J Cardiol 94 1468 1470 10.1016/j.amjcard.2004.07.156 1:CAS:528:DC%2BD2cXhtVWit73K 15566931 (Pubitemid 39556230)
2. VR Babaev F Porro MF Linton S Fazio FE Baralle AF Muro 2008 Absence of regulated splicing of fibronectin EDA exon reduces atherosclerosis in mice Atherosclerosis 197 534 540 10.1016/j.atherosclerosis.2007.08.015 1:CAS:528:DC%2BD1cXktFCks7c%3D 17897651 (Pubitemid 351417892)
3. JD Barrans PD Allen D Stamatiou VJ Dzau CC Liew 2002 Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray Am J Pathol 160 2035 2043 1:CAS:528:DC%2BD38XltFOrs78%3D 12057908
4. A Berndt L Borsi P Hyckel H Kosmehl 2001 Fibrillary co-deposition of laminin-5 and large unspliced tenascin-C in the invasive front of oral squamous cell carcinoma in vivo and in vitro J Cancer Res Clin Oncol 127 286 292 10.1007/s004320000205 1:CAS:528:DC%2BD3MXisVaksbw%3D 11355143 (Pubitemid 32662328)
5. L Borsi E Balza B Gaggero G Allemanni L Zardi 1995 The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH J Biol Chem 270 6243 6245 10.1074/jbc.270.11.6243 1:CAS:528: DyaK2MXksVCnu7g%3D 7534307
6. L Borsi E Balza B Carnemolla F Sassi P Castellani A Berndt H Kosmehl A Biro A Siri P Orecchia J Grassi D Neri L Zardi 2003 Selective targeted delivery of TNFalpha to tumor blood vessels Blood 102 4384 4392 10.1182/blood-2003-04- 1039 1:CAS:528:DC%2BD3sXpslGrsL8%3D 12933583 (Pubitemid 37494099)
7. SS Brack M Silacci M Birchler D Neri 2006 Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C Clin Cancer Res 12 3200 3208 10.1158/1078-0432.CCR-05-2804 1:CAS:528:DC%2BD28Xks1Chsro%3D 16707621 (Pubitemid 43837370)
8. AD Bradshaw CF Baicu TJ Rentz AO Van Laer J Boggs JM Lacy MR Zile 2009 Pressure overload-induced alterations in fibrillar collagen content and myocardial diastolic function: role of secreted protein acidic and rich in cysteine (SPARC) in post-synthetic procollagen processing Circulation 119 269 280 10.1161/CIRCULATIONAHA.108.773424 1:CAS:528:DC%2BD1MXivFeqtg%3D%3D 19118257
9. A Burkauskiene 2005 Age-related changes in the structure of myocardial collagen network of auricle of the right atrium in healthy persons and ischemic heart disease patients Medicina (Kaunas) 41 145 154
10. E El-Emir JL Dearling A Huhalov MP Robson G Boxer D Neri GA van Dongen E Trachsel RH Begent RB Pedley 2007 Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models Br J Cancer 96 1862 1870 10.1038/sj.bjc.6603806 1:CAS:528:DC%2BD2sXmtlyqtbs%3D 17519905 (Pubitemid 46912019)
11. F Farhadian F Contard A Corbier A Barrieux L Rappaport JL Samuel 1995 Fibronectin expression during physiological and pathological cardiac growth J Mol Cell Cardiol 27 981 990 10.1016/0022-2828(95)90067-5 1:CAS:528: DyaK2MXlsl2msbk%3D 7563110
12. O Fondard D Detaint B Iung C Choqueux H Adle-Biassette M Jarraya U Hvass JP Couetil D Henin JB Michel A Vahanian MP Jacob 2005 Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors Eur Heart J 26 1333 1341 10.1093/eurheartj/ehi248 1:CAS:528:DC%2BD2MXmvF2lur4%3D 15827062 (Pubitemid 41435466)
13. M Franz T Hansen P Richter L Borsi FD Bohmer P Hyckel P Schleier D Katenkamp L Zardi H Kosmehl A Berndt 2006 Complex formation of the laminin-5 gamma2 chain and large unspliced tenascin-C in oral squamous cell carcinoma in vitro and in situ: implications for sequential modulation of extracellular matrix in the invasive tumor front Histochem Cell Biol 126 125 131 10.1007/s00418-005-0126-5 1:CAS:528:DC%2BD28XlsFCjsrw%3D 16344911 (Pubitemid 43882546)
14. M Franz A Berndt A Altendorf-Hofmann N Fiedler P Richter J Schumm M Fritzenwanger HR Figulla BR Brehm 2009 Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy Eur J Heart Fail 11 1057 1062 10.1093/eurjhf/hfp128 1:CAS:528:DC%2BD1MXhtlGhsLfN 19815660
15. U Gabler A Berndt H Kosmehl U Mandel L Zardi S Muller A Stelzner D Katenkamp 1996 Matrix remodelling in dilated cardiomyopathy entails the occurrence of oncofetal fibronectin molecular variants Heart 75 358 362 10.1136/hrt.75.4.358 1:STN:280:DyaK283lsF2htQ%3D%3D 8705761
16. A Gabrielsen PR Lawler W Yongzhong D Steinbruchel D Blagoja G Paulsson-Berne J Kastrup GK Hansson 2007 Gene expression signals involved in ischemic injury, extracellular matrix composition and fibrosis defined by global mRNA profiling of the human left ventricular myocardium J Mol Cell Cardiol 42 870 883 10.1016/j.yjmcc.2006.12.016 1:CAS:528:DC%2BD2sXjvFemsrk%3D 17343875 (Pubitemid 46546392)
17. CR Gazoti Debessa LB Mesiano Maifrino R Rodrigues de Souza 2001 Age related changes of the collagen network of the human heart Mech Ageing Dev 122 1049 1058 10.1016/S0047-6374(01)00238-X 1:CAS:528:DC%2BD3MXktVKktbY%3D 11389923 (Pubitemid 32520990)
18. MA Glukhova MG Frid BV Shekhonin TD Vasilevskaya J Grunwald M Saginati VE Koteliansky 1989 Expression of extra domain A fibronectin sequence in vascular smooth muscle cells is phenotype dependent J Cell Biol 109 357 366 10.1083/jcb.109.1.357 1:CAS:528:DyaL1MXkslGgt7o%3D 2663879
19. Graham HK, Horn M, Trafford AW (2007) Extracellular matrix profiles in the progression to heart failure. European Young Physiologists Symposium Keynote Lecture-Bratislava 2007. Acta Physiol (Oxf) 194:3-21
20. JL Hall S Grindle X Han D Fermin S Park Y Chen RJ Bache A Mariash Z Guan S Ormaza J Thompson J Graziano SE de Sam Lazaro S Pan RD Simari LW Miller 2004 Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks Physiol Genomics 17 283 291 10.1152/physiolgenomics.00004.2004 1:CAS:528:DC%2BD2cXltValt78%3D 14872006 (Pubitemid 38924173)
21. N Hayata Y Fujio Y Yamamoto T Iwakura M Obana M Takai T Mohri S Nonen M Maeda J Azuma 2008 Connective tissue growth factor induces cardiac hypertrophy through Akt signaling Biochem Biophys Res Commun 370 274 278 10.1016/j.bbrc.2008.03.100 1:CAS:528:DC%2BD1cXlslCqtrk%3D 18375200
22. DJ Henderson AJ Copp 1998 Versican expression is associated with chamber specification, septation, and valvulogenesis in the developing mouse heart Circ Res 83 523 532 1:CAS:528:DyaK1cXlvFCgu7Y%3D 9734475
23. MH Hessel GB Bleeker JJ Bax MM Henneman B den Adel M Klok MJ Schalij DE Atsma A van der Laarse 2007 Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels Eur J Heart Fail 9 1058 1063 10.1016/j.ejheart.2007.07.007 1:CAS:528:DC%2BD2sXhtFWitr%2FI 17728181 (Pubitemid 47451814)
24. C Hrabchak M Ringuette K Woodhouse 2008 Recombinant mouse SPARC promotes parietal endoderm differentiation and cardiomyogenesis in embryoid bodies Biochem Cell Biol 86 487 499 10.1139/O08-141 1:CAS:528:DC%2BD1cXhsFSmur7P 19088797
25. JJ Hwang PD Allen GC Tseng CW Lam L Fananapazir VJ Dzau CC Liew 2002 Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure Physiol Genomics 10 31 44 1:CAS:528:DC%2BD38XmsFait74%3D 12118103
26. K Imanaka-Yoshida M Hiroe Y Yasutomi T Toyozaki T Tsuchiya N Noda T Maki T Nishikawa T Sakakura T Yoshida 2002 Tenascin-C is a useful marker for disease activity in myocarditis J Pathol 197 388 394 10.1002/path.1131 1:CAS:528:DC%2BD38XmtVSku7Y%3D 12115886 (Pubitemid 34778310)
27. K Imanaka-Yoshida K Matsumoto M Hara T Sakakura T Yoshida 2003 The dynamic expression of tenascin-C and tenascin-X during early heart development in the mouse Differentiation 71 291 298 10.1046/j.1432-0436.2003.7104506.x 1:CAS:528:DC%2BD3sXmsl2ru7Y%3D 12823230 (Pubitemid 36819114)
28. K Imanaka-Yoshida M Hiroe T Yoshida 2004 Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling Histol Histopathol 19 517 525 1:CAS:528:DC%2BD2cXjsVGnt7w%3D 15024713
29. B Iung G Baron EG Butchart F Delahaye C Gohlke-Barwolf OW Levang P Tornos JL Vanoverschelde F Vermeer E Boersma P Ravaud A Vahanian 2003 A prospective survey of patients with valvular heart disease in Europe: the Euro heart survey on valvular heart disease Eur Heart J 24 1231 1243 10.1016/S0195-668X(03)00201-X 12831818 (Pubitemid 36834640)
30. A Jordan V Roldan M Garcia J Monmeneu FG de Burgos GY Lip F Marin 2007 Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis J Intern Med 262 385 392 10.1111/j.1365-2796.2007.01823.x 1:CAS:528:DC%2BD2sXhtFSltLjN 17697160 (Pubitemid 47246973)
31. H Ju IM Dixon 1996 Extracellular matrix and cardiovascular diseases Can J Cardiol 12 1259 1267 1:CAS:528:DyaK2sXntVKjtA%3D%3D 8987966
32. H Kim CS Yoon B Rah 1999 Expression of extracellular matrix components fibronectin and laminin in the human fetal heart Cell Struct Funct 24 19 26 10.1247/csf.24.19 1:CAS:528:DyaK1MXisVagtb4%3D 10355875 (Pubitemid 29161150)
33. HE Kim SS Dalal E Young MJ Legato ML Weisfeldt J D'Armiento 2000 Disruption of the myocardial extracellular matrix leads to cardiac dysfunction J Clin Invest 106 857 866 10.1172/JCI8040 1:CAS:528:DC%2BD3cXntVyiu7k%3D 11018073
34. MM Kittleson KM Minhas RA Irizarry SQ Ye G Edness E Breton JV Conte G Tomaselli JG Garcia JM Hare 2005 Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure Physiol Genomics 21 299 307 10.1152/physiolgenomics.00255.2004 1:CAS:528:DC%2BD2MXpvFOltb0%3D 15769906 (Pubitemid 40903130)
35. MK Magnusson DF Mosher 1998 Fibronectin: structure, assembly, and cardiovascular implications Arterioscler Thromb Vasc Biol 18 1363 1370 1:CAS:528:DyaK1cXmtlyitb8%3D 9743223
36. CM Matter PK Schuler P Alessi P Meier R Ricci D Zhang C Halin P Castellani L Zardi CK Hofer M Montani D Neri TF Luscher 2004 Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin Circ Res 95 1225 1233 10.1161/01.RES.0000150373.15149.ff 1:CAS:528:DC%2BD2cXhtVensrjM 15539632 (Pubitemid 39648214)
37. S Morimoto K Imanaka-Yoshida S Hiramitsu S Kato M Ohtsuki A Uemura Y Kato T Nishikawa T Toyozaki H Hishida T Yoshida M Hiroe 2005 Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis J Pathol 205 460 467 10.1002/path.1730 1:CAS:528:DC%2BD2MXivVynu7o%3D 15685595 (Pubitemid 40361334)
38. V Pelouch IM Dixon R Sethi NS Dhalla 1993 Alteration of collagenous protein profile in congestive heart failure secondary to myocardial infarction Mol Cell Biochem 129 121 131 10.1007/BF00926360 1:CAS:528:DyaK2cXitFChs7g%3D 8177234
39. N Petajaniemi M Korhonen J Kortesmaa K Tryggvason K Sekiguchi H Fujiwara L Sorokin LE Thornell Z Wondimu D Assefa M Patarroyo I Virtanen 2002 Localization of laminin alpha4-chain in developing and adult human tissues J Histochem Cytochem 50 1113 1130 1:CAS:528:DC%2BD38XlvFSjt7g%3D 12133914
40. JT Peterson H Li L Dillon JW Bryant 2000 Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat Cardiovasc Res 46 307 315 10.1016/S0008-6363(00)00029-8 1:CAS:528:DC%2BD3cXisFGqsr0%3D 10773235 (Pubitemid 30204603)
41. V Polyakova S Miyagawa Z Szalay J Risteli S Kostin 2008 Atrial extracellular matrix remodelling in patients with atrial fibrillation J Cell Mol Med 12 189 208 10.1111/j.1582-4934.2008.00219.x 1:CAS:528:DC%2BD1cXltlSqsrg%3D 18194448
42. P Richter M Tost M Franz A Altendorf-Hofmann K Junker L Borsi D Neri H Kosmehl H Wunderlich A Berndt 2009 B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder? J Cancer Res Clin Oncol 135 1351 1358 10.1007/s00432-009-0576-6 1:CAS:528:DC%2BD1MXhtVSitL%2FM 19326143
43. JN Rybak E Trachsel J Scheuermann D Neri 2007 Ligand-based vascular targeting of disease ChemMedChem 2 22 40 10.1002/cmdc.200600181 1:CAS:528:DC%2BD2sXjsVWjsLk%3D 17154429
44. MW Schellings D Vanhoutte M Swinnen JP Cleutjens J Debets RE van Leeuwen J d'Hooge F Van de Werf P Carmeliet YM Pinto EH Sage S Heymans 2009 Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction J Exp Med 206 113 123 10.1084/jem.20081244 1:CAS:528:DC%2BD1MXhtVOhur8%3D 19103879
45. C Schliemann A Wiedmer M Pedretti M Szczepanowski W Klapper D Neri 2009 Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma Leuk Res 33 1718 1722 10.1016/j.leukres.2009.06.025 1:CAS:528:DC%2BD1MXhtFKnsbnE 19625084
46. B Schwartzkopff M Fassbach B Pelzer M Brehm BE Strauer 2002 Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy Eur J Heart Fail 4 439 10.1016/S1388-9842(02)00092-2 1:CAS:528:DC%2BD38XlvF2rurg%3D 12167381 (Pubitemid 36564961)
47. JE Schwarzbauer 1991 Fibronectin: from gene to protein Curr Opin Cell Biol 3 786 791 10.1016/0955-0674(91)90051-Y 1:CAS:528:DyaK38XhvV2ltb8%3D 1931080
48. M Silacci SS Brack N Spath A Buck S Hillinger S Arni W Weder L Zardi D Neri 2006 Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo Protein Eng Des Sel 19 471 478 10.1093/protein/ gzl033 1:CAS:528:DC%2BD28Xps1yhurY%3D 16928692 (Pubitemid 44408907)
49. FG Spinale 2007 Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function Physiol Rev 87 1285 1342 10.1152/physrev.00012.2007 1:CAS:528:DC%2BD2sXhtlaqu7vF 17928585 (Pubitemid 350041472)
50. Swan HJ (1996) Left ventricular dysfunction in ischemic heart disease: fundamental importance of the fibrous matrix. Cardiovasc Drugs Ther 8 Suppl 2:305-312
51. L Tarli E Balza F Viti L Borsi P Castellani D Berndorff L Dinkelborg D Neri L Zardi 1999 A high-affinity human antibody that targets tumoral blood vessels Blood 94 192 198 1:CAS:528:DyaK1MXktlOks74%3D 10381513
52. F Terasaki H Okamoto K Onishi A Sato H Shimomura B Tsukada K Imanaka-Yoshida M Hiroe T Yoshida Y Kitaura A Kitabatake 2007 Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy Circ J 71 327 330 10.1253/circj.71.327 1:CAS:528:DC%2BD2sXjsF2ktrY%3D 17322629 (Pubitemid 46409533)
53. K Toeda K Nakamura S Hirohata OF Hatipoglu K Demircan H Yamawaki H Ogawa S Kusachi Y Shiratori Y Ninomiya 2005 Versican is induced in infiltrating monocytes in myocardial infarction Mol Cell Biochem 280 47 56 10.1007/s11010-005-8051-4 1:CAS:528:DC%2BD2MXht1GlsbzL 16311904 (Pubitemid 41829799)
54. E Trachsel D Neri 2006 Antibodies for angiogenesis inhibition, vascular targeting and endothelial cell transcytosis Adv Drug Deliv Rev 58 735 754 10.1016/j.addr.2005.11.002 1:CAS:528:DC%2BD28XoslKrsbo%3D 16822576 (Pubitemid 44247228)
55. E Trachsel M Kaspar F Bootz M Detmar D Neri 2007 A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo J Invest Dermatol 127 881 886 10.1038/sj.jid.5700653 1:CAS:528: DC%2BD2sXivVGlsb4%3D 17185984 (Pubitemid 46434663)
56. A Villa E Trachsel M Kaspar C Schliemann R Sommavilla JN Rybak C Rosli L Borsi D Neri 2008 A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo Int J Cancer 122 2405 2413 10.1002/ijc.23408 1:CAS:528:DC%2BD1cXltlaitbs%3D 18271006 (Pubitemid 351590471)
57. F Viti L Tarli L Giovannoni L Zardi D Neri 1999 Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis Cancer Res 59 347 352 1:CAS:528: DyaK1MXntFKqtg%3D%3D 9927045
58. T von Lukowicz M Silacci MT Wyss E Trachsel C Lohmann A Buck TF Luscher D Neri CM Matter 2007 Human antibody against C domain of tenascin-C visualizes murine atherosclerotic plaques ex vivo J Nucl Med 48 582 587 10.2967/jnumed.106.036046 (Pubitemid 47571414)
59. IE Willems JW Arends MJ Daemen 1996 Tenascin and fibronectin expression in healing human myocardial scars J Pathol 179 321 325 10.1002/(SICI)1096- 9896(199607)179:3<321::AID-PATH555>3.0.CO;2-8 1:STN:280: DyaK28zntVGqtg%3D%3D 8774490 (Pubitemid 26266413)